Literature DB >> 33517490

PD-1 siRNA-Encapsulated Solid Lipid Nanoparticles Downregulate PD-1 Expression by Macrophages and Inhibit Tumor Growth : PD-1 siRNA-Encapsulated Solid Lipid Nanoparticles.

Mahmoud S Hanafy1,2, Stephanie Hufnagel1, Andrea N Trementozzi3, Wedad Sakran2, Jeanne C Stachowiak3, John J Koleng4, Zhengrong Cui5.   

Abstract

The present study was designed to test the hypothesis that programmed cell death-1 (PD-1) siRNA can downregulate PD-1 expression in macrophages in culture and in tumor tissues in mice and inhibit tumor growth in a mouse model. PD-1 siRNA was encapsulated in solid lipid nanoparticles (SLNs), and the physical properties of the resultant SLNs were characterized. The ability of the PD-1 siRNA-SLNs to downregulate PD-1 expression was confirmed in J774A.1 macrophages in culture and in tumor tissues in mice. Moreover, the antitumor activity of the PD-1 siRNA-SLNs was evaluated in a mouse model. The PD-1 siRNA-SLNs were roughly spherical, and their particle size, polydispersity index, and zeta potential were 141 ± 5 nm, 0.17 ± 0.02, and 20.7 ± 4.7 mV, respectively, with an siRNA entrapment efficiency of 98.9%. The burst release of the PD-1 siRNA from the SLNs was minimal. The PD-1 siRNA-SLNs downregulated PD-1 expression on J774A.1 macrophage cell surface as well as in macrophages in B16-F10 tumors pre-established in mice. In mice with pre-established B16-F10 tumors, the PD-1 siRNA-SLNs significantly inhibited the tumor growth, as compared with siRNA-SLNs prepared with non-functional, negative control siRNA. In conclusion, the PD-1 siRNA-SLNs inhibited tumor growth, likely related to their ability to downregulate PD-1 expression by tumor-associated macrophage (TAMs).

Entities:  

Keywords:  PD-1; macrophages; nanoparticles; siRNA; tumor

Mesh:

Substances:

Year:  2021        PMID: 33517490      PMCID: PMC8500311          DOI: 10.1208/s12249-021-01933-y

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  36 in total

1.  Immunotherapy: Macrophages hijack anti-PD-1 therapy.

Authors:  David Killock
Journal:  Nat Rev Clin Oncol       Date:  2017-05-31       Impact factor: 66.675

2.  The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs.

Authors:  Akin Akinc; Martin A Maier; Muthiah Manoharan; Kevin Fitzgerald; Muthusamy Jayaraman; Scott Barros; Steven Ansell; Xinyao Du; Michael J Hope; Thomas D Madden; Barbara L Mui; Sean C Semple; Ying K Tam; Marco Ciufolini; Dominik Witzigmann; Jayesh A Kulkarni; Roy van der Meel; Pieter R Cullis
Journal:  Nat Nanotechnol       Date:  2019-12       Impact factor: 39.213

3.  The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.

Authors:  Bianca Simon; Dennis C Harrer; Beatrice Schuler-Thurner; Niels Schaft; Gerold Schuler; Jan Dörrie; Ugur Uslu
Journal:  Exp Dermatol       Date:  2018-07       Impact factor: 3.960

Review 4.  Lysosomal Biology in Cancer.

Authors:  Colin Fennelly; Ravi K Amaravadi
Journal:  Methods Mol Biol       Date:  2017

Review 5.  Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.

Authors:  Amy L Shergold; Rhona Millar; Robert J B Nibbs
Journal:  Pharmacol Res       Date:  2019-05-04       Impact factor: 7.658

6.  Different patterns of macrophage infiltration into allogeneic-murine and xenogeneic-human neoplasms growing in nude mice.

Authors:  C D Bucana; A Fabra; R Sanchez; I J Fidler
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

Review 7.  Gene therapy using bacterial vectors.

Authors:  Peter Celec; Roman Gardlik
Journal:  Front Biosci (Landmark Ed)       Date:  2017-01-01

8.  Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.

Authors:  Pooja Dhupkar; Nancy Gordon; John Stewart; Eugenie S Kleinerman
Journal:  Cancer Med       Date:  2018-05-07       Impact factor: 4.452

9.  PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression.

Authors:  Francesca R Mariotti; Stefania Petrini; Tiziano Ingegnere; Nicola Tumino; Francesca Besi; Francesca Scordamaglia; Enrico Munari; Silvia Pesce; Emanuela Marcenaro; Alessandro Moretta; Paola Vacca; Lorenzo Moretta
Journal:  Oncoimmunology       Date:  2018-12-25       Impact factor: 8.110

10.  RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.

Authors:  Byunghee Yoo; Veronica Clavijo Jordan; Patrick Sheedy; Ann-Marie Billig; Alana Ross; Pamela Pantazopoulos; Zdravka Medarova
Journal:  Sci Rep       Date:  2019-03-18       Impact factor: 4.379

View more
  3 in total

Review 1.  Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.

Authors:  Yuan Zhang; Juhura G Almazi; Hui Xin Ong; Matt D Johansen; Scott Ledger; Daniela Traini; Philip M Hansbro; Anthony D Kelleher; Chantelle L Ahlenstiel
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923

Review 2.  Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application.

Authors:  Yulin Fan; Zhijun Yang
Journal:  Pharmaceutics       Date:  2022-06-02       Impact factor: 6.525

Review 3.  Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics.

Authors:  Mina Zare; Rakesh Pemmada; Maya Madhavan; Aswathy Shailaja; Seeram Ramakrishna; Sumodan Padikkala Kandiyil; James M Donahue; Vinoy Thomas
Journal:  Pharmaceutics       Date:  2022-08-03       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.